Compare Abeona Therapeutics Inc (ABEO) vs Beyond Meat Inc (BYND) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Beyond Meat Inc — how do they compare? Abeona Therapeutics Inc trades at $6.75 (market cap $373.32M), while Beyond Meat Inc trades at $0.68 (market cap $366.00M). The key difference: Abeona Therapeutics Inc and Beyond Meat Inc are close in size by market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Beyond Meat Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | BYND | |
|---|---|---|
Market Cap | $373.32M | $366.00M |
Sector | Health | Consumer Staples |
52-Week High | $7.23 | $4.28 |
52-Week Low | $4.17 | $0.52 |
Enterprise Value | $228.22M | $675.99M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
BYND trades at $0.7102, down slightly by 0.01% on the day, with a neutral technical signal and bearish moving averages. The company reported a net income of $178.01M in 2025, a significant turnaround from prior losses, though revenue declined to $275.50M. Recent news highlights expansion of Beyond Steak Filet into major retailers like Meijer and Wegmans, alongside new product launches such as Beyond Immerse protein drinks, aiming to revive growth amid challenging sales trends.
The outlook remains cautious due to persistent revenue declines and negative cash flow from operations, offset by strong profitability margins and positive net income. Risks include execution challenges in new product categories and high sell-side analyst skepticism, with 57.14% recommending sell. Investment opportunity hinges on successful turnaround efforts driving sustainable top-line growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Beyond Meat Inc
Beyond Meat is a provider of plant-based meats, such as burgers, sausage, ground beef, and chicken. Unlike other vegetarian products, Beyond Meat seeks to replicate the look, cook, and taste of meat, is targeted to omnivores and vegetarians alike, and is sold in the meat case. The products are widely available across the U.S. and Canada and in 83 additional countries as well. International revenue represented 31% of 2021 sales. The firm's products are available in retail stores and the food-service channel. In 2019, before the pandemic struck, sales were evenly split between these two channels, although mix stood at 70% retail/30% food service in 2021. We think the recovery from the crisis and new deals with McDonald's and Yum Brands will return food-service sales to nearly 50% in time.
Read more on BYND →
